Spexis Provides Business Update and Announces Financial Results for the Full-Year 2021

Successful launch of Spexis AG as a reverse merger of Polyphor AG with EnBiotix Inc.Successful closing of a USD 12.8 million pre-merger financingFirst patient enrollment and start of Phase 1 trial for inhaled murepavadinStart of COPILOT, the first …